What is OS Therapies's R&D?

OS Therapies (OSTX) reported R&D of $7.35M in Q1 2026.

How has OS Therapies's R&D changed year-over-year?

OS Therapies's R&D increased by 461.6% year-over-year, from $1.31M to $7.35M.

What is the long-term trend for OS Therapies's R&D?

Over 2 years (2023 to 2025), OS Therapies's R&D has grown at a 125.4% compound annual growth rate (CAGR), from $3.22M to $16.36M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

OS Therapies OSTX R&D

R&D at other companies

ImmunomeIMNM

$46.38M+25.8%

CTO

Citius Oncology, Inc.CTOR

$1.08M-65.6%

Avalo TherapeuticsAVTX

$14.05M+54.0%

Arcus BiosciencesRCUS

$122M0.0%

WHW

Whitehawk Therapeutics, Inc. Common StockWHWK

$17.23M+96.1%

ImmunityBio, Inc.IBRX

——

Segments

By segment

See full

Chief Operating Decision Maker$7.35M+462%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+66.4%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's R&D?: OS Therapies (OSTX) reported R&D of $7.35M in Q1 2026.
How has OS Therapies's R&D changed year-over-year?: OS Therapies's R&D increased by 461.6% year-over-year, from $1.31M to $7.35M.
What is the long-term trend for OS Therapies's R&D?: Over 2 years (2023 to 2025), OS Therapies's R&D has grown at a 125.4% compound annual growth rate (CAGR), from $3.22M to $16.36M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.